ダウンロード数: 1467

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
57_7.pdf970.54 kBAdobe PDF見る/開く
タイトル: 過活動膀胱症状を有する前立腺肥大症に対するナフトピジルの有効性の検討 : 朝投与と夕投与の前向き無作為化比較試験
その他のタイトル: Efficacy of Naftopidil in Patients with Overactive Bladder Associated with Benign Prostatic Hyperplasia: Prospective Randomized Controlled Study to Compare Differences in Efficacy Between Morning and Evening Medication
著者: 酒井, 英樹  KAKEN_name
井川, 掌  KAKEN_name
大仁田, 亨  KAKEN_name
古川, 正隆  KAKEN_name
計屋, 知彰  KAKEN_name
林, 幹男  KAKEN_name
松屋, 福蔵  KAKEN_name
志田, 洋平  KAKEN_name
西村, 直樹  KAKEN_name
与儀, 安男  KAKEN_name
鶴崎, 俊文  KAKEN_name
竹原, 浩介  KAKEN_name
野俣, 浩一郎  KAKEN_name
白石, 和孝  KAKEN_name
正野, 武文  KAKEN_name
青木, 大勇  KAKEN_name
金武, 洋  KAKEN_name
著者名の別形: Sakai, Hideki
Igawa, Tsukasa
Onita, Toru
Furukawa, Masataka
Hakariya, Tomoaki
Hayashi, Mikio
Matsuya, Fukuzo
Shida, Yohei
Nishimura, Naoki
Yogi, Yasuo
Tsurusaki, Toshifumi
Takehara, Kousuke
Nomata, Koichiro
Shiraishi, Kazutaka
Shono, Takefumi
Aoki, Daiyu
Kanetake, Hiroshi
キーワード: Benign prostatic hyperplasia
Overactive bladder
Naftopidil
Timing of administration
発行日: Jan-2011
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 57
号: 1
開始ページ: 7
終了ページ: 13
抄録: A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects betwen the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.
著作権等: 許諾条件により本文は2012-02-01に公開
URI: http://hdl.handle.net/2433/135441
PubMed ID: 21304253
出現コレクション:Vol.57 No.1

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。